Dr. Manus Rogan, Ph.D, MBA

Dr Manus Rogan is a Managing Partner and co-founder of Fountain Healthcare Partners. He has over 27 years of investment and operating experience in the life science sector in both the US and Europe. Manus earned a PhD in chemistry from the University of York (sponsored by GlaxoSmithKline) and an MBA from Trinity College Dublin.

Manus began his career in product development at GlaxoSmithkline in the UK and in 1996 joined Elan Corporation’s business development group. For four years he was responsible for licensing products and drug delivery technologies in Europe and Japan. In 2001, Manus joined Elan’s Corporate Venture Capital group in New York where he invested in private and public biotechnology companies. Investments included Sirna (acquired by Merck, 2006) and Beyond Genomics (IPO, 2011). In his 7 years at Elan, Manus concluded over twenty five investment and technology licensing transactions involving companies in the US, Europe and Japan.

Manus led Fountain’s investment in Innocoll Inc. and currently serves on the boards of Priothera ltd and Neuromod Devices. He was formerly Chairman of the Irish Venture Capital Association (‘IVCA’) and previously represented Fountain on the boards of Amarin Corporation, Opsona Therapeutics, Inflazome (sold to Roche, 2020) and Mainstay Medical (IPO, 2014).

Aidan King, MBA, CFA

Aidan King is Managing Partner and co-founder of Fountain Healthcare Partners. Aidan qualified as a pharmacist from Trinity College Dublin and in 1992 joined Elan Corporation’s strategic marketing group with the responsibility of identifying and evaluating product development candidates for Elan’s drug delivery technologies. In 1996, Aidan assumed Head of Strategic Marketing for Elan’s drug delivery division with a focus on competitive analysis and strategic positioning of Elan’s technology platforms.

Having completed an MBA at University College Dublin in 1998, Aidan moved to the U.S. as one of the founding members of Elan’s corporate venture capital group. Over the next five years, Aidan undertook over twenty strategic investments in public and private specialty pharma, biotechnology and medical device companies, in the U.S., Canada and Europe. Investments included Quadrant Healthcare (acquired by Elan, 2000), Atrix laboratories (acquired by QLT, 2004), Idun Pharmaceuticals (acquired by Pfizer, 2005) and Zealand Pharmaceuticals (IPO, 2010).

In 2004, Aidan joined Bio-IB, a New York based boutique life science investment bank where he was responsible for M&A and strategic licensing transactions. Aidan is a CFA charter holder. He currently sits on the boards of Xylocor Therapeutics, Corteria Pharmaceuticals and Ermium Therapeutics. Previously, he was the firm’s representative on the boards of Syndesi Therapeutics (acquired by Abbvie, 2022), Civitas Therapeutics (acquired by Acorda, 2014), Chrono Therapeutics, Velicept Therapeutics and Palyon Medical.

Dr. Ena Prosser, Ph.D.

Dr Ena Prosser is a Partner in Fountain Healthcare Partners since the initial fund raising in 2008 and the two subsequent funds. Ena is a PhD biotechnologist by training and has a broad background in investment, international alliance and intellectual property management. She has led due diligence projects on technologies and products within the specialty pharma, diagnostic, device and biotechnology areas. At Fountain, Ena has led several investment including Genable (Ire) Ltd (sold to Spark Therapeutics Inc in 2013), led the Series B investment in NeRRe Therapeutics(UK) Ltd and KaNDy Therapeutics (UK) Ltd (acquired by Bayer, 2020), joined the board of Inotrem S.A. in Paris in 2020 and Netherlands-based Calypso Biotech in 2021.

Ena was formerly Director of BioResearch Ireland at Enterprise Ireland. In this role, she led a large team to identify, fund, protect and exploit relevant Intellectual Property, commercialise lifescience technologies and review investment opportunities in R&D.

Prior to Enterprise Ireland, Ena held various R&D and project management roles within Elan Corporation and had extensive involvement in drug delivery development, licensing and acquisition projects over a 9-year period. Ena has a strong innovation policy background and was a member of the Irish Government Innovation Taskforce in Intellectual Property, ICSTI and Knowledge Transfer Ireland. Ena works closely with leading ophthalmology research charity Fighting Blindness Ireland and the INFANT Research Center based in UCC (Ireland). Ena is an Adjunct Professor at University College Dublin and a member of the Institute of Directors (Ireland).

Justin Lynch, MBA

Justin Lynch is a Partner in Fountain Healthcare Partners. He joined the team over a year prior to the launch of Fund I in 2008. Justin has a BA in Accounting & Finance from Dublin City University, an MBA from Trinity College Dublin and is a member of the Chartered Institute of Management Accountants. He has over 25 years experience in capital markets, corporate finance, entrepreneurial and venture investing across multiple sectors, the latter half in life science.

Justin began his career as a research analyst at NCB stockbrokers in 1985. During this time, Justin had analytical responsibility for 13 companies accounting for 25% of the capitalisation of the Irish Stock Exchange. In 1988, Justin joined the Corporate Finance group of Fyffes plc where his activities included the execution of a number of M&A and financial transactions. He subsequently held a similar senior Corporate Finance role with the Jones Group plc for several years before returning full time to Trinity College to complete an MBA.

After completing his MBA in 1997, Justin co-founded Legend Care and developed a series of medical hosiery devices including a preventive foot care device for diabetic foot disease which is presently in a physician led 400 patient longitudinal multi-centre RCT in the US and the UK, funded by the NIDDK, US National Institutes of Health. Justin has a particular interest in the medical device sector. He led the firms investments in Vivasure Medical, Medical Microinstruments (MMI) and Neurent Medical and previously represented Fountain on the board of Neuravi (acquired by J&J, 2017)

Ruthanne Monaghan, FCCA

Ruthanne Monaghan is the Chief Financial Officer in Fountain Healthcare Partners with responsibility for the finance function, joining the team in 2020. She has over 21 years’ experience in venture capital, corporate finance, group finance and corporate governance across multiple sectors.

Ruthanne began her career as an investment accountant in IPSI, Irish Life and joined Trinity Venture Capital, a technology-focussed venture capital firm in 2004. She worked initially as financial controller and subsequently as investment associate in TVC until 2013, being involved in all aspects of due diligence, investment analysis and M&A activity. She was integrally involved in the IPO of TVC in 2007 when the company transitioned to a private equity public company and represented TVC on the boards of Dalata Hotel Group and CR2 Limited.

Ruthanne joined Mainstream Renewable Power in 2013 in a senior finance role, and in 2015 joined Hostelworld Group plc prior to its IPO on the London and Dublin stock exchanges. Ruthanne was head of the finance function in Hostelworld until 2020, leading a large team and managing all public company compliance, tax planning and reporting, aswell as project managing group restructuring and M&A integrations. She was interim Chief Financial Officer in 2018, with responsibility for investor relations.

Ruthanne has a Bachelor of Commerce from UCD, qualified as an accountant with the ACCA in 2003 and has a certificate in company secretarial law & practice from the Law Society of Ireland.

Tania Papkovskaia, Ph.D.

Dr Tania Papkovskaia is Senior Associate at Fountain Healthcare Partners. Tania qualified with a BSc in Biochemistry from University College Dublin in 2009 and earned a PhD in Clinical Neuroscience from University College London, sponsored by Eisai Limited in collaboration with the Welcome Trust Consortium and the Institute of Neurology. Her research was focused on Leucine Rich Repeat Kinase 2 in Parkinson’s Disease. In addition, she conducted postdoctoral research at the department of Oncology, University of Cambridge, investigating the role of cyclin depended kinase inhibitors in neuroblastoma.

In 2014, Tania joined the Healthcare team at the Gerson Lehrman Group, providing diligence support to global healthcare investors, coordinating business development efforts and product campaigns across pharmaceutical, biotechnology and medical device segments. In 2017, she took over the European Healthcare team, a $4.5 million division, with responsibility spanning revenue, commercial strategy, operational performance, training and development.